# OnCo record qt-prolongation-monitoring-on-anticancer-drugs (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/qt-prolongation-monitoring-on-anticancer-drugs/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "qt-prolongation-monitoring-on-anticancer-drugs" ;
  schema:name "QT prolongation on cancer medicines: ECG and blood salt monitoring, and when to pause or stop"@en ;
  schema:alternateName "QTc monitoring"@en, "long QT on cancer treatment"@en, "ECG before ribociclib"@en, "ECG monitoring on quizartinib"@en, "QTcF"@en, "Fridericia correction"@en, "torsades de pointes"@en, "drug-induced long QT"@en, "heart tracing on cancer tablets"@en ;
  schema:description "Some cancer medicines slow the heart's electrical reset between beats, seen on a heart tracing (ECG) as a long QT interval. Rarely this sets off a dangerous rhythm. Your team should do an ECG and check your blood salts before you start, review your other medicines, and repeat the ECG on a schedule. Get medical help straight away if you faint, feel dizzy or your heartbeat is fast or irregular."@en ;
  schema:url <https://onco.cc/protocols/qt-prolongation-monitoring-on-anticancer-drugs/> ;
  schema:dateModified "2026-11-17"^^xsd:date ;
  onco:tag "protocol", "cardio-oncology", "side-effect-management" ;
  onco:related <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/>, <https://onco.cc/protocols/hypomagnesaemia-on-egfr-antibodies/>, <https://onco.cc/protocols/anticancer-drug-interaction-review/>, <https://onco.cc/key-papers/paper-lyon-eur-heart-j/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:drugs <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/drugs/quizartinib/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/drugs/midostaurin/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/nilotinib/>, <https://onco.cc/drugs/vandetanib/>, <https://onco.cc/drugs/arsenic-trioxide/>, <https://onco.cc/drugs/glasdegib/>, <https://onco.cc/drugs/toremifene/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/drugs/sunitinib/> ;
  onco:institutions <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/qt-prolongation/>, <https://onco.cc/terms/cardiotoxicity/> .
